Boehringer Ingelheim secures novel immune checkpoint inhibitor with acquisition of Nerio Therapeutics

Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline as the company is adding an innovative preclinical program with the acquisition of Nerio Therapeutics Inc. (“Nerio”) for a total of up to USD 1.3 billion. Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio to achieve its aim of improving cancer patient outcomes.

Nerio’s small molecules inhibit the protein tyrosine phosphatases N1 and N2 (PTPN1 and PTPN2), which act as immune checkpoints. Through this mechanism, PTPN1/2 inhibition can activate the immune system to fight cancer cells. 

Immune checkpoint blockade with current checkpoint inhibitors has transformed the cancer treatment landscape. However, while this approach works for some patients, it does not provide a therapeutic benefit for all.  Boehringer Ingelheim is committed to changing this paradigm and extending the benefits of immuno-oncology to more cancer patients with a comprehensive portfolio of therapies based on immune checkpoint blockade to boost the immune system and direct it toward cancer cells. Nerio’s small molecule inhibitors will be an important addition to Boehringer Ingelheim’s portfolio with the potential to act as a single agent therapy and, importantly, in combination with many cancer therapies already being developed in-house.

“Securing the rights to Nerio Therapeutics' novel checkpoint inhibitors creates a broad panel of exciting new cancer treatment combination opportunities. This brings us a major step closer to our vision of transforming the lives of people living with cancer,” said Paola Casarosa, Member of the Board of Managing Directors at Boehringer Ingelheim with responsibility for the Innovation Unit.

Sanford Madigan, partner at Avalon BioVentures, L.P. and co-founder and CEO of Nerio Therapeutics, shares this excitement stating, “We believe Nerio’s small molecule PTPN1/N2 inhibitors have superior drug-like properties and provide a first-in-class opportunity. We are excited to expand Boehringer Ingelheim’s pipeline and commend their commitment to unlock the full potential of our compounds and their mechanistically unique approach to fighting cancer.” 

This acquisition is a bold step toward transforming cancer care. It further strengthens Boehringer Ingelheim’s oncology pipeline of cancer cell-directed and immuno-oncology investigational therapies for smart combinations that may offer the greatest benefit for people living with cancer.

About Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at. www.boehringer-ingelheim.com.

About Nerio Therapeutics

Nerio Therapeutics, Inc. is a drug discovery and development company focused on phosphatases, a notoriously difficult class of potentially high-value therapeutic protein targets. Nerio has developed novel, potent, and highly selective PTPN2/N1 inhibitors with excellent drug-like properties. Nerio’s first-in-class PTPN2/N1 inhibitors enhance immune function and sensitize tumors to pro-inflammatory signals, promoting robust anti-tumor activity. Nerio was founded by Avalon Ventures and had additional financial support from a syndicate including Bregua Corporation, Correlation Ventures, Alexandria Venture Investments and Viva BioInnovator.  Nerio was developed in the Avalon BioVentures accelerator, benefiting from their resident expertise in early-stage drug development and comprehensive company support.